Hyponatremia etiology and tolvaptan: Are we optimally targeting the mechanism?

Arif Asif, Ketan Ghate, Neena Jube, Syed S. Haqqie, Roy O. Mathew, Vishesh Kumar, John Tietjen, John Rosenberger, Sunil Pokharel, Syed F. Saeed, Shervin Yousefian, Donna Merrill, Rizwan Shahid, Muhammad U T Akmal, Ali Nayer, Darius Mason, Tushar Vachharajani, Loay Salman

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Hyponatremia is associated with increased morbidity and mortality. Water restriction is usually the prescribed treatment for most forms of asymptomatic hyponatremia. An oral vasopressin V2-receptor antagonist, tolvaptan has been successfully used in the treatment of asymptomatic hyponatremia. In this retrospective study, tolvaptan (n=40) and a control group (n=40) were compared for asymptomatic hyponatremia etiology and response to treatment. The syndrome of inappropriate anti-diuretic hormone (SIADH) and congestive heart failure (CHF) were the most common causes of asymptomatic hyponatremia that were treated with tolvaptan. Of note, the cause of hyponatremia was not clarified in 50% of the control and 10% of the tolvaptan group. In the tolvaptan group, serum sodium concentration increased from 125±4.2 to 136±2.1 mEq/L (mean±SD, P<0.001) over 5±2 days while the control group did not show any change from its baseline value of 129.9±3 vs 128±4 mEq/L. SIADH and CHF were the most common disorders associated with asymptomatic hyponatremia and treated with tolvaptan. Importantly, 50% of the asymptomatic hyponatremia patients in the control group were labeled as unclear etiology and did not receive tolvaptan. Increased awareness of the etiology and mechanisms of asymptomatic hyponatremia development can identify individuals who benefit from tolvaptan therapy.

Original languageEnglish (US)
Pages (from-to)8-11
Number of pages4
JournalOpen Urology and Nephrology Journal
Volume7
Issue number1
StatePublished - 2014

Fingerprint

Hyponatremia
Diuretics
Control Groups
Heart Failure
Hormones
tolvaptan
Vasopressin Receptors
Therapeutics
Retrospective Studies
Sodium
Morbidity
Mortality
Water

Keywords

  • Hyponatremia
  • Serum osmolality
  • Serum sodium
  • Tolvaptan
  • Urine osmolality

ASJC Scopus subject areas

  • Nephrology
  • Urology

Cite this

Asif, A., Ghate, K., Jube, N., Haqqie, S. S., Mathew, R. O., Kumar, V., ... Salman, L. (2014). Hyponatremia etiology and tolvaptan: Are we optimally targeting the mechanism? Open Urology and Nephrology Journal, 7(1), 8-11.

Hyponatremia etiology and tolvaptan : Are we optimally targeting the mechanism? / Asif, Arif; Ghate, Ketan; Jube, Neena; Haqqie, Syed S.; Mathew, Roy O.; Kumar, Vishesh; Tietjen, John; Rosenberger, John; Pokharel, Sunil; Saeed, Syed F.; Yousefian, Shervin; Merrill, Donna; Shahid, Rizwan; Akmal, Muhammad U T; Nayer, Ali; Mason, Darius; Vachharajani, Tushar; Salman, Loay.

In: Open Urology and Nephrology Journal, Vol. 7, No. 1, 2014, p. 8-11.

Research output: Contribution to journalArticle

Asif, A, Ghate, K, Jube, N, Haqqie, SS, Mathew, RO, Kumar, V, Tietjen, J, Rosenberger, J, Pokharel, S, Saeed, SF, Yousefian, S, Merrill, D, Shahid, R, Akmal, MUT, Nayer, A, Mason, D, Vachharajani, T & Salman, L 2014, 'Hyponatremia etiology and tolvaptan: Are we optimally targeting the mechanism?', Open Urology and Nephrology Journal, vol. 7, no. 1, pp. 8-11.
Asif A, Ghate K, Jube N, Haqqie SS, Mathew RO, Kumar V et al. Hyponatremia etiology and tolvaptan: Are we optimally targeting the mechanism? Open Urology and Nephrology Journal. 2014;7(1):8-11.
Asif, Arif ; Ghate, Ketan ; Jube, Neena ; Haqqie, Syed S. ; Mathew, Roy O. ; Kumar, Vishesh ; Tietjen, John ; Rosenberger, John ; Pokharel, Sunil ; Saeed, Syed F. ; Yousefian, Shervin ; Merrill, Donna ; Shahid, Rizwan ; Akmal, Muhammad U T ; Nayer, Ali ; Mason, Darius ; Vachharajani, Tushar ; Salman, Loay. / Hyponatremia etiology and tolvaptan : Are we optimally targeting the mechanism?. In: Open Urology and Nephrology Journal. 2014 ; Vol. 7, No. 1. pp. 8-11.
@article{6601d8ded53746478127c29dc736e907,
title = "Hyponatremia etiology and tolvaptan: Are we optimally targeting the mechanism?",
abstract = "Hyponatremia is associated with increased morbidity and mortality. Water restriction is usually the prescribed treatment for most forms of asymptomatic hyponatremia. An oral vasopressin V2-receptor antagonist, tolvaptan has been successfully used in the treatment of asymptomatic hyponatremia. In this retrospective study, tolvaptan (n=40) and a control group (n=40) were compared for asymptomatic hyponatremia etiology and response to treatment. The syndrome of inappropriate anti-diuretic hormone (SIADH) and congestive heart failure (CHF) were the most common causes of asymptomatic hyponatremia that were treated with tolvaptan. Of note, the cause of hyponatremia was not clarified in 50{\%} of the control and 10{\%} of the tolvaptan group. In the tolvaptan group, serum sodium concentration increased from 125±4.2 to 136±2.1 mEq/L (mean±SD, P<0.001) over 5±2 days while the control group did not show any change from its baseline value of 129.9±3 vs 128±4 mEq/L. SIADH and CHF were the most common disorders associated with asymptomatic hyponatremia and treated with tolvaptan. Importantly, 50{\%} of the asymptomatic hyponatremia patients in the control group were labeled as unclear etiology and did not receive tolvaptan. Increased awareness of the etiology and mechanisms of asymptomatic hyponatremia development can identify individuals who benefit from tolvaptan therapy.",
keywords = "Hyponatremia, Serum osmolality, Serum sodium, Tolvaptan, Urine osmolality",
author = "Arif Asif and Ketan Ghate and Neena Jube and Haqqie, {Syed S.} and Mathew, {Roy O.} and Vishesh Kumar and John Tietjen and John Rosenberger and Sunil Pokharel and Saeed, {Syed F.} and Shervin Yousefian and Donna Merrill and Rizwan Shahid and Akmal, {Muhammad U T} and Ali Nayer and Darius Mason and Tushar Vachharajani and Loay Salman",
year = "2014",
language = "English (US)",
volume = "7",
pages = "8--11",
journal = "Open Urology and Nephrology Journal",
issn = "1874-303X",
publisher = "Bentham Science Publishers B.V.",
number = "1",

}

TY - JOUR

T1 - Hyponatremia etiology and tolvaptan

T2 - Are we optimally targeting the mechanism?

AU - Asif, Arif

AU - Ghate, Ketan

AU - Jube, Neena

AU - Haqqie, Syed S.

AU - Mathew, Roy O.

AU - Kumar, Vishesh

AU - Tietjen, John

AU - Rosenberger, John

AU - Pokharel, Sunil

AU - Saeed, Syed F.

AU - Yousefian, Shervin

AU - Merrill, Donna

AU - Shahid, Rizwan

AU - Akmal, Muhammad U T

AU - Nayer, Ali

AU - Mason, Darius

AU - Vachharajani, Tushar

AU - Salman, Loay

PY - 2014

Y1 - 2014

N2 - Hyponatremia is associated with increased morbidity and mortality. Water restriction is usually the prescribed treatment for most forms of asymptomatic hyponatremia. An oral vasopressin V2-receptor antagonist, tolvaptan has been successfully used in the treatment of asymptomatic hyponatremia. In this retrospective study, tolvaptan (n=40) and a control group (n=40) were compared for asymptomatic hyponatremia etiology and response to treatment. The syndrome of inappropriate anti-diuretic hormone (SIADH) and congestive heart failure (CHF) were the most common causes of asymptomatic hyponatremia that were treated with tolvaptan. Of note, the cause of hyponatremia was not clarified in 50% of the control and 10% of the tolvaptan group. In the tolvaptan group, serum sodium concentration increased from 125±4.2 to 136±2.1 mEq/L (mean±SD, P<0.001) over 5±2 days while the control group did not show any change from its baseline value of 129.9±3 vs 128±4 mEq/L. SIADH and CHF were the most common disorders associated with asymptomatic hyponatremia and treated with tolvaptan. Importantly, 50% of the asymptomatic hyponatremia patients in the control group were labeled as unclear etiology and did not receive tolvaptan. Increased awareness of the etiology and mechanisms of asymptomatic hyponatremia development can identify individuals who benefit from tolvaptan therapy.

AB - Hyponatremia is associated with increased morbidity and mortality. Water restriction is usually the prescribed treatment for most forms of asymptomatic hyponatremia. An oral vasopressin V2-receptor antagonist, tolvaptan has been successfully used in the treatment of asymptomatic hyponatremia. In this retrospective study, tolvaptan (n=40) and a control group (n=40) were compared for asymptomatic hyponatremia etiology and response to treatment. The syndrome of inappropriate anti-diuretic hormone (SIADH) and congestive heart failure (CHF) were the most common causes of asymptomatic hyponatremia that were treated with tolvaptan. Of note, the cause of hyponatremia was not clarified in 50% of the control and 10% of the tolvaptan group. In the tolvaptan group, serum sodium concentration increased from 125±4.2 to 136±2.1 mEq/L (mean±SD, P<0.001) over 5±2 days while the control group did not show any change from its baseline value of 129.9±3 vs 128±4 mEq/L. SIADH and CHF were the most common disorders associated with asymptomatic hyponatremia and treated with tolvaptan. Importantly, 50% of the asymptomatic hyponatremia patients in the control group were labeled as unclear etiology and did not receive tolvaptan. Increased awareness of the etiology and mechanisms of asymptomatic hyponatremia development can identify individuals who benefit from tolvaptan therapy.

KW - Hyponatremia

KW - Serum osmolality

KW - Serum sodium

KW - Tolvaptan

KW - Urine osmolality

UR - http://www.scopus.com/inward/record.url?scp=84930505154&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930505154&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84930505154

VL - 7

SP - 8

EP - 11

JO - Open Urology and Nephrology Journal

JF - Open Urology and Nephrology Journal

SN - 1874-303X

IS - 1

ER -